Revenue Cycle AI Premium: What Should Providers Pay For?

Revenue Cycle Management (RCM) AI Pricing Needs A Demand Test. | Question The AI Upgrade

Healthcare providers are facing an uncomfortable question: Are they requesting AI-enabled upgrades, or are vendors creating demand by making AI the default version of products already in use? An unsolicited AI upgrade may simply be a renewal increase with new implementation risk.

Becker’s Hospital Review described tools returning at renewal with an AI label, higher pricing or consumption fees, while the underlying workflow remained largely unchanged. For healthcare CFOs, chief revenue officers, revenue cycle leaders and technology executives, the buying test should therefore begin with business demand: Which problem did we ask the vendor to solve, and what materially changes for patients, staff or cash performance?

Providers Should Test The Value Before Paying An AI Premium.

Before accepting higher pricing, leaders should ask for a side-by-side comparison of the current and AI-enabled versions. What new decisions can it make? Which handoffs or queues disappear? What human review remains? Can the provider retain the existing version?

The vendor should also disclose why the price is rising. Some premiums may reflect real costs, including model inference, cloud infrastructure, security, monitoring, support and ongoing model improvement. Others may reflect opportunistic packaging or an attempt to protect the vendor from its own unpredictable AI bill. Providers should require cost-driver transparency, usage assumptions and evidence that the premium is proportional to incremental value.

Providers Need To Distinguish Transformation From Automation. | Separate AI from automation

AI is most defensible when work contains variability, incomplete information, unstructured content or multi-step judgment that rules-based automation cannot handle well. Ordinary automation remains the better choice for stable, deterministic tasks with explicit rules. Adding a probabilistic model to reliable rules can increase cost without changing the result.

The practical test is whether the end-to-end workflow changes. True transformation should prevent work, resolve exceptions, improve decisions or close a process with fewer human touches. If employees must validate every output, correct avoidable errors or manage additional exception queues, the technology may have shifted labor rather than eliminated it.

Revenue Cycle AI Can Prove Value In Targeted Workflows. | Prove Revenue Cycle Value

Evidence points to targeted opportunities rather than universal readiness. An HFMA poll found interest in documentation and coding, prior authorization, denials and underpayment management, but only a minority of surveyed organizations reported positive ROI. McKinsey highlights the back end as a practical starting point for agentic AI, while Oliver Wyman reports early scale across coding, clinical documentation integrity, prior authorization and related functions.

Credible use cases have measurable volume, expensive manual work and clear financial consequences. Examples include preventing coding or claim errors before submission, prioritizing denials by recoverability, identifying underpayments, assembling authorization evidence and automating status follow-up. Claims of a fully autonomous, touchless revenue cycle deserve more skepticism where payer behavior, fragmented data, clinical ambiguity or policy variation still demand expert intervention.

Prove AI Value Before Scaling.

A proof-of-value should begin with a jointly approved baseline covering volume, unit cost, cycle time, accuracy, first-pass performance, exception rates, staffing effort, cash impact and downstream rework. The baseline should reflect payer mix and normal variability, while recording parallel changes that could distort attribution.

Testing should use representative production conditions and predetermined success thresholds. Finance should validate the economics, operations should validate workflow impact, IT should validate reliability and data leaders should validate input quality. NIST’s AI Risk Management Framework provides a useful governance logic: govern, map, measure and manage risk throughout the AI lifecycle.

The strongest metric is cost per successful outcome, not activity completed. A transaction counts as successful only when it meets quality requirements without avoidable correction. This exposes solutions that process work faster but increase rework, denials, false recommendations or staff review downstream.

‍

AI Pricing Can Learn From The Cloud Transition | Choose A Pricing Model

The move from licensed software to cloud subscriptions taught providers that flexible consumption can improve access while weakening budget predictability. Initial unit rates can appear attractive, yet adoption, data movement, integrations and unused commitments can drive the total bill. The lesson is to establish visibility, allocation, forecasting and optimization before scale.

AI adds another layer because tokens are technical units rather than business outcomes. Costs can vary with document length, prompt design, model choice, retries, tool calls and output length. The FinOps Foundation recommends inventory, account and API-key governance, allocation data and model right-sizing to manage token economics. Revenue cycle leaders should translate tokens into cost per claim, authorization, call, note or resolved account, then into cost per accurate completion.

Transaction-Based Pricing Can Provide An Interim Middle Ground.

FTE-based pricing rewards labor deployment rather than better performance. Pure outcome-based pricing can be difficult when attribution is disputed or the vendor controls the outcome definition. Transaction-based pricing can be a useful middle ground because it connects fees to observable workflow volume while preserving budget visibility.

The contract must define the transaction precisely. Leaders should distinguish attempts from successfully completed work, exclude duplicates and failed retries, establish tiered rates, cap exposure and retain audit rights. For higher-risk workflows, use a modest platform fee, a transparent price per successful transaction and a limited performance component.

Providers Must Evaluate Productivity Alongside Rework. | Measure Risk And Rework

Productivity should never be evaluated without model variability, inaccurate recommendations, workflow disruption and human oversight. Leaders should measure the full exception pathway: frequency, severity, detection time, correction effort and financial or patient impact. Even a small error rate can destroy value when errors are costly.

First-pass performance makes the trade-off visible. If AI completes more work correctly on the first attempt, it can release capacity and accelerate cash. If apparent productivity depends on reviewers catching errors later, rework has merely been displaced. Open accountability requires the vendor and provider to share performance data, root causes, corrective actions and the cost of exceptions rather than debating responsibility after the fact.

Disciplined AI Governance Balances Innovation, Cost And Control. | Govern AI At Scale

Disciplined governance should combine a centralized portfolio view with accountable workflow ownership. Every use case needs an executive sponsor, operational owner, financial baseline, risk classification, approved data access, proof-of-value plan and defined scale or exit decision. A cross-functional forum should include revenue cycle, Finance, IT, data, compliance, security and clinical leadership where appropriate.

The portfolio should reveal overlapping pilots, cumulative consumption and vendor concentration. Contracts should preserve data portability, exit rights, pricing transparency and performance evidence.

The goal is to prevent uncontrolled spending, fragmented experiments and lock-in. The CFO’s position can be straightforward: providers should pay more when AI demonstrably changes an outcome, not merely when a vendor changes the product label.

‍